About: Vadastuximab talirine

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid lineage. The experimental drug, being developed by Seattle Genetics, was in clinical trials for the treatment of acute myeloid leukemia (AML). Development of vadastuximab talirine was discontinued in 2017 after a pivotal phase III clinical trial.

Property	Value
dbo:abstract	Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid lineage. The experimental drug, being developed by Seattle Genetics, was in clinical trials for the treatment of acute myeloid leukemia (AML). Development of vadastuximab talirine was discontinued in 2017 after a pivotal phase III clinical trial. (en)
dbo:casNumber	1436390-64-5
dbo:fdaUniiCode	T13V17U431
dbo:thumbnail	wiki-commons:Special:FilePath/Vadastuximab_talirine.svg?width=300
dbo:wikiPageID	41331931 (xsd:integer)
dbo:wikiPageLength	6617 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1124010320 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Decitabine dbr:Antibody-drug_conjugate dbc:Pyrrolobenzodiazepines dbc:Antibody-drug_conjugates dbr:Orphan_drug dbr:Myelodysplastic_syndrome dbr:Clinical_trials dbr:Pyrrolobenzodiazepine dbr:Azacitidine dbr:U.S._Food_and_Drug_Administration dbr:Acute_myeloid_leukemia dbr:American_Society_of_Hematology dbr:European_Commission dbr:Hypomethylating_agent dbc:Monoclonal_antibodies dbr:CD33 dbr:Cathepsin_B dbr:Seattle_Genetics
dbp:atcPrefix	none (en)
dbp:casNumber	1436390 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:mabType	mab (en)
dbp:source	xi/o (en)
dbp:synonyms	SGN-CD33A (en)
dbp:target	dbr:CD33
dbp:type	mab (en)
dbp:unii	T13V17U431 (en)
dbp:width	250 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Fdacite dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Pyrrolobenzodiazepines dbc:Antibody-drug_conjugates dbc:Monoclonal_antibodies
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid lineage. The experimental drug, being developed by Seattle Genetics, was in clinical trials for the treatment of acute myeloid leukemia (AML). Development of vadastuximab talirine was discontinued in 2017 after a pivotal phase III clinical trial. (en)
rdfs:label	Vadastuximab talirine (en)
owl:sameAs	wikidata:Vadastuximab talirine https://global.dbpedia.org/id/fZPb
prov:wasDerivedFrom	wikipedia-en:Vadastuximab_talirine?oldid=1124010320&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Vadastuximab_talirine.svg
foaf:isPrimaryTopicOf	wikipedia-en:Vadastuximab_talirine
is dbo:wikiPageRedirects of	dbr:Vadastuximab_talirine_(SGN-CD33A) dbr:SGN-CD33A dbr:Vadastuximab
is dbo:wikiPageWikiLink of	dbr:Vadastuximab_talirine_(SGN-CD33A) dbr:SGN-CD33A dbr:Pyrrolobenzodiazepine dbr:Vadastuximab dbr:List_of_therapeutic_monoclonal_antibodies dbr:Rovalpituzumab_tesirine
is foaf:primaryTopic of	wikipedia-en:Vadastuximab_talirine